Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
about
A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophreniaDefinitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewEfficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.Symptom, family, and service predictors of children's psychiatric rehospitalization within one year of discharge.Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses based on SADS-L.Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia.Cost comparisons of olanzapine and risperidone in treating schizophrenia.Novel antipsychotics in the long-term treatment of schizophrenia.Risperidone: a review.Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study.Risperidone long-acting injection.Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol.Long-term treatment with flupentixol results of a post-marketing surveillance study.Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine.Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications.The cost of relapse in schizophrenia and schizoaffective disorder.Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015.Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.Correlates of readmission risk and readmission days in a large psychiatric hospital in Guangzhou, China.
P2860
Q24794849-404397A3-FF19-4C06-956A-21D5FB4EA6A8Q33589087-D2D6D166-26FD-412D-B4B9-4EC99E65D6C1Q33738740-ED7866E9-4D7D-47F0-B71D-4199895A9A5DQ34193279-39129D2F-3682-4890-9CCC-3ADC42986157Q34952432-9F097617-22A5-4C98-9C66-6EA199A8B0C2Q35101645-A8B8ED93-6AF1-4874-9270-C3988089F9F0Q35638077-EE07C858-80BC-434A-95B7-C3A6CD7CE8F6Q35719339-8501A4E1-A923-4284-BFD7-A4ED1A339676Q36150794-1AC80919-ABB9-4F93-B6CC-0DA1A011CADBQ36370291-DB70FB81-C578-4B29-A911-F2ECF04A8164Q36609365-DDD48644-DA01-42FC-93B7-15644844E697Q43265614-5A55A1DD-8D2E-4BA0-B14D-C078A98A6FA9Q45029914-3FD267BF-47CE-4518-8CDA-8ABE5EBCE841Q46533489-25F6C4D6-E8E9-4122-99DC-F90143518BBBQ46837812-83978EBD-F872-48AA-B253-BFB8235F6453Q46896761-69603EA5-A298-4CC2-898D-E8E0C8A31A60Q46984989-B51C14A1-7C1B-48B7-A0DC-5FB49705DB3FQ50114703-0FB993A9-FBA1-4C3C-8BFD-04557933771CQ50802689-C6A887F3-B642-48B0-AC0D-27E56538B923Q51866468-5D39832E-0AFA-4093-BDE5-2AB7A34995ACQ51920285-6EC8A3C0-AB78-4F75-A475-F33F75EBCC61Q52673029-42704B38-A339-487D-80E6-2C9216863EE8Q52800015-C6DCDA71-2745-4AC9-A64A-4BC52F4F5BE6Q53103334-EF69E958-24D1-41A1-B96F-0FA03045C315
P2860
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rehospitalization rates of chr ...... r conventional antipsychotics.
@ast
Rehospitalization rates of chr ...... r conventional antipsychotics.
@en
type
label
Rehospitalization rates of chr ...... r conventional antipsychotics.
@ast
Rehospitalization rates of chr ...... r conventional antipsychotics.
@en
prefLabel
Rehospitalization rates of chr ...... r conventional antipsychotics.
@ast
Rehospitalization rates of chr ...... r conventional antipsychotics.
@en
P2093
P1476
Rehospitalization rates of chr ...... r conventional antipsychotics.
@en
P2093
P304
P356
10.1176/APPI.AJP.158.2.266
P407
P577
2001-02-01T00:00:00Z